EHA 2024: Highlights in Multiple Myeloma

Joseph Mikhael, MD, discusses the latest trends and innovations regarding multiple myeloma management.

Joseph Mikhael, MD, discusses the latest trends and innovations regarding multiple myeloma management.

Joseph Mikhael, MD, discusses the PERSEUS trial findings presented at EHA 2024.

Dr. Mikhael discusses treatment in early relapse of multiple myeloma.

Dr. Mikhael discusses the safety and usefulness of tesclistimab in patients with high-risk refractory multiple myeloma.

Dr. Mikhael outlines the significant hurdles in bispecific antibody therapy, as presented at the European Hematology Association's 2024 conference.

Dr. Mikhael discusses EHA 2024 data he found particularly noteworthy to share with colleagues.